Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    Academia’s Role in Drug Discovery

    There’s a new Viewpoint piece out in ACS Medicinal Chemistry Letters on academia and drug discovery. Donna Huryn of Pittsburgh is wondering about the wisdom of trying to reproduce a drug-company environment inside a university: However, rather than asking how a university can mimic a drug discovery company, perhaps a better question is what u… Read More
  • Academia (vs. Industry)

    Advice For Those Trying High-Throughput Screening

    So here’s a question that a lot of people around here will have strong opinions on. I’ve heard from someone in an academic group that’s looking into doing some high-throughput screening. As they put it, they don’t want to end up as “one of those groups”, so they’re looking for advice on how to get… Read More
  • Academia (vs. Industry)

    Another Controversial Scaffold?

    My post the other day on a very unattractive screening hit/tool compound prompted a reader to mention this paper. It’s one from industry this time (AstraZeneca), and at first it looks like similarly foul chemical matter. But I think it’s worth a closer look, to see how they dealt with what they’d been given by… Read More
  • Academia (vs. Industry)

    Rearrange Those Chemists

    See Ahr Oh has a handy map of all the big recent faculty moves in the organic chemistry world, to help you keep up. Note that Nicolaou-to-Rice is still a dotted line. Read More
  • Academia (vs. Industry)

    Science Fiction Gets the Upper Hand

    I wrote here about the Cronin lab at Glasgow and their work on using 3-D printing technology to make small chemical reactors. Now there’s an article on this research in the Observer that’s getting some press attention (several people have e-mailed it to me). Unfortunately, the headline gets across the tone of the whole piece: Read More
  • Academia (vs. Industry)

    Cheer For Good Ol’ Pfizer U

    The biggest pharma companies increasingly seem to feel as if they need universities nearby. We’ve talked about this trend before, and Pfizer’s current strategy makes it quite clear. Partnerships between industry and academia, of course, aren’t new. Yet Pfizer, Sanofi, Merck & Co. (MRK) and other drug companies are putting a new t… Read More
  • Academia (vs. Industry)

    Lessons For a New Medicinal Chemist

    I gave my talk at the Drew University Medicinal Chemistry course, and it got me to thinking about when I was there (1990 or 1991), and my early days in medicinal chemistry in general. There are a lot of things that have to be learned when coming out of a synthetic organic chemistry background, and… Read More
  • Academia (vs. Industry)

    Return of the Rhodanome

    I do hate to bring up rhodanines again, but I’m not the one who keeps making the things. This paper from ACS Medicinal Chemistry Letters turns out dozens of the things as potential inhibitors of the cellular protein dynamin, in what a colleague of mine referred to as a “nice exploration of the rhodanome”. He… Read More
  • Academia (vs. Industry)

    Anonymous Grant Review Gets A Try

    Anonymity is a topic that comes up whenever you talk about commenting on published scientific work. Some people are very uncomfortable with the idea of others being able to take potshots at them from behind convenient rocks, while others think that without that ability, a lot of relevant discussion will never take place. Similar concerns… Read More
  • Academia (vs. Industry)

    The NIH’s Drug Repurposing Initiative: Will It Be a Waste?

    The NIH’s attempt to repurpose shelved development compounds and other older drugs is underway: The National Institutes of Health (NIH) today announced a new plan for boosting drug development: It has reached a deal with three major pharmaceutical companies to share abandoned experimental drugs with academic researchers so they can look for n… Read More
...567...